Vanta Bioscience Ltd (540729) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 540729 | NSE: | Business Support | Small Cap

Vanta Bioscience Share Price

19.61 -1.84 -8.58%
as on 05-Dec'25 13:27

Vanta Bioscience Ltd (540729) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 540729 | NSE: | Business Support | Small Cap

DeciZen - make an informed investing decision on Vanta Bioscience

Based on:

M-Cap below 100cr DeciZen not available

Vanta Bioscience stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
15.3 Cr.
52-wk low:
19.1
52-wk high:
49.9

Is Vanta Bioscience Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Vanta Bioscience: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Vanta Bioscience Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 0%0%2.5%8.8%8.9%6.8%5.2%-2.4%5.4%-4.4%-
Value Creation
Index
NANA-0.8-0.4-0.4-0.5-0.6-1.2-0.6-1.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 003.912.113.79.89.45.28.61.11
Sales YoY Gr.-NANA211.3%13.6%-28.4%-4.8%-44.7%65.6%-86.8%-
Adj EPS 00-00.91.40.80.1-6.70.1-4.3-3.7
YoY Gr.-NANANA64.4%-45.5%-85.9%-6209.1%NA-8600%-
BVPS (₹) 016.92935.237.137.93831.331.427.129.7
Adj Net
Profit
00-00.60.90.50.1-4.20-2.7-3
Cash Flow from Ops. 0-0.3-6.8-0.13.2116.70.64.51.4-
Debt/CF from Ops. 0-28.3-1.7-215.74.51.63.1405.622.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA-39.3%-50.6%-86.8%
Adj EPS NA-224.3%-438.1%-8600%
BVPSNA-6.1%-10.6%-13.5%
Share Price - -32.5% -36.3% -56.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
00-0.12.842.10.3-19.40.2-14.5-13.2
Op. Profit
Mgn %
0026.627.231.540.236.4-9.242.8-146.9NAN
Net Profit
Mgn %
00-0.24.66.650.7-820.4-238.1-235.3
Debt to
Equity
01.20.70.60.60.70.91.31.31.8-
Working Cap
Days
002352513905774907914923,5870
Cash Conv.
Cycle
001411933194643284842432,5830

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Vanta Bioscience Ltd.

Standalone Consolidated
TTM EPS (₹) -3.7 -6.7
TTM Sales (₹ Cr.) 1.1 2
BVPS (₹.) 29.7 20.3
Reserves (₹ Cr.) 14 7
P/BV 0.72 1.06
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 19.08 / 49.86
All Time Low / High (₹) 19.08 / 195.50
Market Cap (₹ Cr.) 15.3
Equity (₹ Cr.) 7.1
Face Value (₹) 10
Industry PE 38.7

Management X-Ray of Vanta Bioscience:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Vanta Bioscience - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Vanta Bioscience

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales03.8812.0813.729.829.355.178.561.13
Operating Expenses 02.858.819.415.925.955.654.912.78
Manufacturing Costs00.311.171.240.690.740.720.910.33
Material Costs00.321.401.180.820.620.680.271.06
Employee Cost 01.612.903.792.512.572.752.680.58
Other Costs 00.603.333.191.912.011.491.050.81
Operating Profit 01.033.274.323.893.40-0.483.65-1.66
Operating Profit Margin (%) -26.6%27.1%31.5%39.7%36.4%-9.2%42.7%-146.0%
Other Income 00.050.230.110.020.170.630.050.04
Interest 00.201.691.952.062.113.112.420.66
Depreciation 00.570.711.191.251.321.251.240.44
Exceptional Items 000000000
Profit Before Tax 00.311.101.290.610.14-4.210.04-2.72
Tax 00.290.400.310.130.060.03-0.01-0.06
Profit After Tax 00.030.690.980.470.08-4.240.05-2.66
PAT Margin (%) -0.7%5.7%7.1%4.8%0.8%-81.9%0.6%-235.0%
Adjusted EPS (₹)0.00.11.11.60.80.1-6.70.1-4.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 6.1516.5922.2523.4423.9123.9919.7419.7917.13
Share Capital 3.655.736.316.316.316.316.316.316.31
Reserves 2.5010.8615.9317.1317.6017.6813.4313.4810.82
Minority Interest000000000
Debt7.5010.4812.1712.3113.3017.1422.5520.9325.20
Long Term Debt7.509.9812.1710.4310.7715.6420.8418.1119.39
Short Term Debt00.5001.882.531.501.712.825.81
Trade Payables00.190.460.490.471.472.362.222.69
Others Liabilities 0.101.933.255.508.627.856.989.9710.80
Total Liabilities 13.7529.1938.1241.7446.3050.4451.6452.9255.84

Fixed Assets

Gross Block12.9518.0619.1823.2333.1141.1643.6945.3451.13
Accumulated Depreciation00.571.282.473.725.046.297.468.69
Net Fixed Assets 12.9517.4917.9020.7629.3936.1237.4037.8742.43
CWIP 02.343.70000000
Investments 04.503.95333333
Inventories03.029.2414.019.767.247.167.486.48
Trade Receivables00.331.561.361.980.721.922.341.74
Cash Equivalents 0.440.090.280.090.070.070.070.140.14
Others Assets 0.361.421.482.542.103.302.092.082.03
Total Assets 13.7529.1938.1241.7446.3050.4451.6452.9255.84

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -0.26-6.75-0.063.1711.016.700.644.541.36
PBT 00.311.101.290.610.14-4.210.04-2.72
Adjustment 00.732.403.143.293.434.363.621.89
Changes in Working Capital -0.26-7.8-3.56-1.267.113.130.490.892.19
Tax Paid 0000000-0.010
Cash Flow From Investing Activity -12.95-7.53-4.48-1.35-9.86-8.05-2.53-1.67-5.79
Capex -12.95-2.60-2.48-0.35-0.86-8.05-2.530.090
Net Investments 0-0.080000000
Others 0-4.86-2-1-900-1.75-5.79
Cash Flow From Financing Activity 13.6613.934.73-2.02-1.171.351.88-2.804.43
Net Proceeds from Shares 6.1510.414.96000000
Net Proceeds from Borrowing 7.502.482.19-1.740.341.405.20-2.731.28
Interest Paid 0-0.16-1.69-1.95-2.06-2.11-3.11-2.42-0.66
Dividend Paid 000000000
Others 0.011.20-0.731.670.552.07-0.212.353.81
Net Cash Flow 0.44-0.360.20-0.20-0.020-00.070

Finance Ratio

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)00.243.574.281.990.33-19.370.26-14.4
ROCE (%)02.478.818.866.765.24-2.445.43-4.43
Asset Turnover Ratio00.190.370.350.230.190.10.160.02
PAT to CFO Conversion(x)N/A-225-0.093.2323.4383.75N/A90.8N/A
Working Capital Days
Receivable Days030283861539391661
Inventory Days02771803014323325083122,261
Payable Days0220851472135661,0233,147844

Vanta Bioscience Ltd Stock News

Vanta Bioscience Ltd FAQs

The current trading price of Vanta Bioscience on 05-Dec-2025 13:27 is ₹19.61.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Vanta Bioscience stood at ₹15.26.
The latest P/E ratio of Vanta Bioscience as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Vanta Bioscience as of 04-Dec-2025 is 0.72.
The 52-week high of Vanta Bioscience is ₹49.86 and the 52-week low is ₹19.08.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vanta Bioscience is ₹1.13 ( Cr.) .

About Vanta Bioscience Ltd

Vanta Bioscience (VBS) was originally incorporated as a private limited company under the Companies Act, 2013 pursuant to a certificate of incorporation issued by the Registrar of Companies, Hyderabad dated April 29, 2016 with the name ‘Vanta Bioscience Private Limited’. Their Company was converted into a public limited company pursuant to approval of the shareholders at an extraordinary general meeting held on February 13, 2017 and consequently, the name of the Company was changed to ‘Vanta Bioscience Limited’ and a fresh certificate of incorporation consequent upon conversion to public limited company was issued by the Registrar of Companies, Hyderabad on March 17, 2017.

One of the major services of VBL is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. The relationship between dose and its effects on the exposed organism is of high significance in toxicology. Toxicology and safety assessment are sometimes used interchangeably and considered as synonymous.

Business area of the company

The company is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition they also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation.

Major Events & Milestones:

  • 2016: Incorporation of the Company.
  • 2017:  The Company concluded the purchase of the preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as - Vanta Bioscience? (a toxicology division of Kemin Industries South Asia Private Limited) along with leasehold rights in 4.8 acres of land situated at Plot K2B, SIPCOT Industrial Estate, Gummidipundi, Chennai - 601 201.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×